BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38648728)

  • 1. Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma.
    Robinson RM; Reyes L; Duncan RM; Bian H; Reitz AB; Manevich Y; McClure JJ; Champion MM; Chou CJ; Sharik ME; Chesi M; Bergsagel PL; Dolloff NG
    Leukemia; 2019 Apr; 33(4):1011-1022. PubMed ID: 30315229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.
    Zhou J; Chng WJ
    World J Clin Oncol; 2019 Sep; 10(9):303-306. PubMed ID: 31572666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.
    Yang J; Yu YC; Wang ZX; Li QQ; Ding N; Leng XJ; Cai J; Zhang MY; Wang JJ; Zhou Y; Wei TH; Xue X; Dai WC; Sun SL; Yang Y; Li NG; Shi ZH
    Eur J Med Chem; 2024 May; 271():116435. PubMed ID: 38648728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
    Abramson HN
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):611-627. PubMed ID: 30001985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Experimental Drugs for Treatment of Multiple Myeloma.
    Offidani M; Corvatta L; Morè S; Olivieri A
    J Exp Pharmacol; 2021; 13():245-264. PubMed ID: 33727866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New prognostic biomarkers in multiple myeloma.
    Szudy-Szczyrek A; Szczyrek M; Soroka-Wojtaszko M; Hus M
    Postepy Hig Med Dosw (Online); 2016 Jan; 70(0):811-9. PubMed ID: 27463592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma.
    Davis LN; Sherbenou DW
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918370
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.